Effects of Alkaline Phosphatase on Renal Function in Septic Patients
Maneno muhimu
Kikemikali
Tarehe
Imethibitishwa Mwisho: | 02/28/2006 |
Iliyowasilishwa Kwanza: | 04/03/2007 |
Uandikishaji uliokadiriwa Uliwasilishwa: | 04/04/2007 |
Iliyotumwa Kwanza: | 04/05/2007 |
Sasisho la Mwisho Liliwasilishwa: | 04/04/2007 |
Sasisho la Mwisho Lilichapishwa: | 04/05/2007 |
Tarehe halisi ya kuanza kwa masomo: | 10/31/2004 |
Tarehe ya Kukamilisha Utafiti: | 02/28/2006 |
Hali au ugonjwa
Uingiliaji / matibabu
Drug: bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)
Awamu
Vigezo vya Kustahiki
Zama zinazostahiki Kujifunza | 18 Years Kwa 18 Years |
Jinsia Inastahiki Kujifunza | All |
Hupokea Wajitolea wa Afya | Ndio |
Vigezo | Inclusion Criteria: - Written informed consent - Proven or suspected Gram-negative bacterial infection - Two out of four Systemic Inflammatory Response Syndrome (SIRS) criteria existing for less than 24 h - Acute onset of end-organ dysfunction in the preceding 12 h Exclusion Criteria: - Prior therapy with alkaline phosphatase - Known allergy for cow milk - Probable death within 24 h - Chronic renal failure requiring hemodialysis or peritoneal dialysis - Acute pancreatitis with no established source of infection - HIV seropositive - Pregnant or lactating - Confirmed Gram-positive or fungal sepsis - Treatment with immunosuppressants including high doses of glucocorticosteroids |
Matokeo
Hatua za Matokeo ya Msingi
1. Biomarkers of kidney damage [undefined]
2. kidney function [undefined]
3. markers of inflammation [undefined]